Clinical-stage ophthalmology company, Kubota Vision, a subsidiary of Tokyo-based Kubota Pharmaceutical Holdings, announced a collaboration with India’s Aurolab to license development , manufacturing, and distributing its medical device eyeMO in India, South Asia and other underserved Asian/African/Latin American markets.
EyeMO is a low-cost, home-based, ophthalmic self-monitoring OCT (Optical Coherence Tomography) device. This small handheld device addresses needs in mobile health applications for self-monitoring of retina health by patients in the home and in remote field locations. The device detects nascent disease progression, and aims to improve ophthalmic treatment outcomes in patients diagnosed with and treated for wet age-related macular degeneration, diabetic macular edema and other vascular retinal diseases.
Aurolab, based in India’s southern state of Tamil Nadu, manufactures ophthalmic consumables such as intraocular lenses, surgical sutures, pharmaceuticals, surgical blades.
Kubota Vision’s Chairman CEO Ryo Kubota believes combining cost-effectiveness and performance is key for promoting global adoption of eyeMO. The portable, easy-to-use OCT device is critical for limited-resource countries where patient access to clinics is challenging.
AUROLAB’s managing director R.D. Sriram also emphasized eyeMO’s value for such low-resource settings through this partnership.
